Canine mandibular osteosarcoma: 51 cases (1980-1992)

1996 ◽  
Vol 32 (3) ◽  
pp. 257-262 ◽  
Author(s):  
RC Straw ◽  
BE Powers ◽  
J Klausner ◽  
RA Henderson ◽  
WB Morrison ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Survival Rate ◽  
Histological Grade ◽  
Survival Outcome ◽  
Hazard Ratio ◽  
Treatment Modalities ◽  
Apparent Effect ◽  
Histological Score ◽  
One Year ◽  
The One

Fifty-one dogs treated for mandibular osteosarcomas (OSs) were studied retrospectively. Treatments were partial mandibulectomy (n = 32); partial mandibulectomy and chemotherapy (n = 10); partial mandibulectomy and radiation therapy (n = 3); partial mandibulectomy, radiation therapy, and chemotherapy (n = 4); and radiation therapy alone (n = 2). The overall one-year survival rate was 59.3%. Dogs treated with surgery alone had a one-year survival rate of 71%, which is higher than the one-year survival rate for dogs with appendicular OSs treated with surgery alone (p of 0.001 or less; hazard ratio of 0.29). There was no apparent effect of various treatment modalities, nor institution where treatment was given, nor histological type. Histological score and, to a lesser extent, histological grade were predictive of survival outcome.

scholarly journals Comparative analysis of long-term treatment outcomes in patients with locally advanced prostate cancer

2021 ◽  
Vol 20 (2) ◽  
pp. 23-27
Author(s):  
G. V. Galina ◽  
Р. A. Karnaukh ◽  
D. M. Timokhina ◽  
E. A. Kyprianov
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Survival Rate ◽  
Hormone Therapy ◽  
Survival Rates ◽  
Pelvic Lymphadenectomy ◽  
Adjuvant Hormone Therapy ◽  
One Year ◽  
The One ◽  
Group 1

Introduction. The aim of the study was to compare the survival rates of patients with prostate cancer (PC) with lymphogenic metastases (N1) after surgical treatment and after conformal distant radiation therapy followed by adjuvant hormone therapy with analogues of luteinizing-releasing hormone (LHRH).Materials and methods. The patients were divided into two groups. The first group included 36 patients with prostate cancer after posadilonic prostatectomy with extended pelvic lymphadenectomy followed by continuous adjuvant hormone therapy (analogs of LGRH) for up to two to three years. Lymphogenic metastases were detected after histological examination of the operative material. The second group consisted of 42 patients after neoadjuvant hormone therapy for 6 months (LGRH analogues), a course of distant radiation therapy (DLT) in the traditional mode with a single focal dose (ROD) of 2 Gray (Gy), a total focal dose (SOD) of 72 Gy, followed by adjuvant hormone therapy in a continuous mode (analogs of LGRH) for up to two to three years.Results. The duration of follow-up was 60 months, with a median of 38 months. The one-year survival rate after surgery was 86.1%, in the group after DLT — 81.2%, the three-year survival rate in group 1 — 80.1%, in group 2 — 76.3%, the five-year survival rates — 72.3% and 69.1% respectively. The one-year cancer-specific survival rate in group 1 was 96.7%, the three-year survival rate was 83.4%, and the five-year survival rate was 52.8%. In the second group, the oneyear survival rate was 91.9%, the three-year survival rate was 74.1%, and the five-year survival rate was 51.4%. Conclusion. For the treatment of prostate cancer patients with lymphogenic metastases, prostatectomy with extended pelvic lymphadenectomy can be considered as a treatment option not only in clinical trials. The results of cancer-specific and relapse-free survival show the effectiveness of this treatment option

Renal Transplantation—A Tale of Two Cities

1980 ◽  
Vol 25 (4) ◽  
pp. 269-274
Author(s):  
R. F. M. Wood ◽  
P. R. F. Bell ◽  
J. Walls ◽  
J. R. Nash ◽  
D. S. MacPherson ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Survival Rate ◽  
Graft Survival ◽  
Initial Experience ◽  
Tissue Typing ◽  
Two Cities ◽  
Transplant Team ◽  
The Difference ◽  
One Year ◽  
The One

In 1974 three members of the transplant team from the Western Infirmary in Glasgow moved to the new medical school in Leicester. The initial experience with 33 patients transplanted in Glasgow was published in 1972 and this paper compares the results of that series with the first 21 patients grafted in Leicester. Despite improvements in tissue typing, better quality donor kidneys and fewer complications, there has been a failure to improve on the levels of graft survival. The overall one year graft survival rate in the Glasgow series was 79 per cent compared to 52 per cent in Leicester. In these two series the difference in results appears to be explained by blood transfusion. All the Glasgow patients had been poly-transfused but of the Leicester patients the 10 transfused pre-transplant had a one year graft survival of 90 per cent while in the 11 non-transfused patients the one year graft survival was only 18 per cent.

Gemcitabine, oxaliplatin and weekly high-dose 5-FU as a 24-hr-infusion in chemonaive patients with advanced or metastatic carcinoma of the gallbladder: Preliminary results of a multicenter phase II-study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4129-4129 ◽  
Author(s):  
A. D. Wagner ◽  
P. Buechner-Steudel ◽  
H. Schmalenberg ◽  
M. Moehler ◽  
O. Kuss ◽  
...  
Keyword(s):  
Survival Rate ◽  
Median Survival ◽  
Phase Ii ◽  
Tumor Response ◽  
Phase Ii Study ◽  
Metastatic Carcinoma ◽  
Phase Iii ◽  
Carcinoma Of The Gallbladder ◽  
One Year ◽  
The One

4129 Background: Combinations of gemcitabine (GEM)/5-FU, GEM/oxaliplatin (LOHP) or 5-FU/LOHP work synergistically in pancreatic and/or colorectal malignancies, and have non-overlapping safety profiles. This phase II-study was designed to evaluate the efficacy and safety of the triple combination GEM/LOHP/5-FU in patients (pts) with advanced or metastatic carcinoma of the gallbladder. Methods: One-stage, multicentre phase II study. Eligibility criteria: chemonaive pts with histologically proven advanced, recurrent or metastatic gallbladder carcinoma (ECOG 0–1; expected survival >3 months; measurable disease; adequate renal, hepatic and bone marrow function). According to the results of our previous phase I-study (Proc ASCO 2003, # 1298), pts were treated with GEM 900mg/m2 as a 30-min infusion, followed by LOHP 65 mg/m2 (2-hr infusion) after a 30 min rest and 5-FU 1500 mg/m2 (24-hr-infusion) on d 1, 8, every 3 weeks. Planned sample size: 35 response evaluable patients. The primary endpoint was tumor response, secondary endpoints were toxicity, median survival, the one-year-survival rate, clinical benefit and quality of life. Results: At time of abstract submission, median follow-up of 35 enrolled pts is 9.8 months. Pt. characteristics: m/f: 11/24, median age 61 (range 42–81), ECOG 0/1: 24/11 (69/31%) pts, locally advanced/metastatic disease 1/32 (3/91%) pts. Analysis of tumor response is still pending. Grade III/IV (NCI-CTC) toxicities occurred in 36/3% of 191 cycles and were: leucopenia 3/1%, neutropenia 4/1%, thrombocytopenia 4/1%, anemia 2/0%, nausea 1/0%, sensory neuropathy 4/0%, asthenia 1/0%, elevated bilirubin 2/0%, AP 4/0%, or elevated SGOT/SGPT 1/0%, edema 1/0%, infection 1/0%, dyspnoe 1/1%. Median survival of all pts is 9.9 months (95% CI: 7.5–11.5), the one-year-survival-rate is 30 % (95% CI: 16–47). Conclusions: GEM/LOHP/5-FU combination therapy is tolerated well in patients with gallbladder cancer. The promising survival data has to be confirmed in a phase III study. (Supported by grants from Eli Lilly and Company, Indianapolis, IN, USA and Sanofi-Synthelabo, Paris, France). [Table: see text]

scholarly journals Analysis of Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Infection and Its Effect on the Outcome of Early Infection After Kidney Transplantation

2021 ◽  
Vol 11 ◽  
Author(s):  
Fei Zhang ◽  
Jinbiao Zhong ◽  
Handong Ding ◽  
Jiashan Pan ◽  
Jing Yang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Survival Rate ◽  
Klebsiella Pneumoniae ◽  
Postoperative Mortality ◽  
Effective Prevention ◽  
Carbapenem Resistant ◽  
Kaplan Meier ◽  
Total Prevalence ◽  
One Year ◽  
The One

BackgroundInfections remain a major cause of morbidity and mortality in kidney transplant (KT) recipients. This study was performed to identify the overall prevalence of early infections, prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infection after KT, one-year postoperative mortality in patients with early infections and risk factors for CRKP infections.MethodsWe conducted a retrospective study of all patients who received KT in our hospital between January 2017 and December 2019. We evaluated the demographic, clinical, infection characteristics and the one-year postoperative outcomes.ResultsAmong the 419 patients who received KT between January 2017 and December 2019, 150 patients had at least one infection within 90 days after KT. The total prevalence of early infections was 36.1% (150/415), the prevalence of early CRKP infections was 10.4% (43/415), and the one-year postoperative mortality was 15.3% (23/150) in patients with early infections. The risk factors independently related to one-year postoperative mortality were mechanical ventilation (MV) > 48 h (Odds ratio (OR)= 13.879, 95%Confidence interval (CI): 2.265~85.035; P=0.004) and CRKP infection (OR=6.751, 95% CI: 1.051~43.369; P =0.044). MV> 48 h was independently related to CRKP infection (OR=3.719, 95% CI: 1.024~13.504; P=0.046). Kaplan-Meier survival curves showed that the one-year survival rate of patients infected with CRKP in the early postoperative stage was significantly lower than that of uninfected patients.ConclusionsIn general, the prevalence of early infections after KT is high, and CRKP infection is closely correlated with poor prognosis. The effective prevention and treatment of CRKP infection is an important way to improve the one-year survival rate after KT.

scholarly journals Establishment of white poplar clonal plantations by stools

Topola ◽  
2021 ◽  
pp. 11-20
Author(s):  
Branislav Kovačević ◽  
Duško Bastajić ◽  
Slađana Dabić ◽  
Zoran Novčić ◽  
Zoran Galić ◽  
...  
Keyword(s):  
Survival Rate ◽  
Deep Level ◽  
Underground Water ◽  
High Survival ◽  
White Poplar ◽  
Rooted Cuttings ◽  
Clonal Plantation ◽  
Poplar Plantations ◽  
One Year ◽  
The One

The results of white poplar clonal plantation establishment by stools are presented. The trials were established at three sites, characterized by favorable water regime for growth and development of poplars. Also, the effect of different factors on survival rate, diameter at breast height and plants' height was analyzed. Results suggest that similar high survival rate (90-100%) was achieved by planting of stools on depth of 2.5 m (deep planting), as it was achieved by planting of rooted cuttings at the depth of 0.8 m, which is a comon practise in the establishment of white poplar plantations. The survival rate of planted stools did not decrease signifficantly between the end of the first and second growing season. Selected clones achieved survival rate of Villafranca clone with both methods of planting. Two-year old rootless shoots (2/0 type of plantings) achieved higher survival rate than the one-year old ones (1/0 type) and two-year old rooted cuttings (2/2 type). Survival rate of one-year old rootless shoots (1/0 type) planted at the depth of 0.8 m was not significantly lower than of those planted at the depth of 2.5 m, but it was notably lower than survival rate of rooted cuttings (1/1 type). Establishment of white poplar clones by stools could significantly improve white poplar wood production, considering the benefits of plants production in stool beds. The potential for improvement of the establishment of white poplar plantations on sandy soils with relatively deep level of underground water, and the potential for successful planting of difficult-to-root white poplar genotypes, should be the subject of further studies.

scholarly journals Reevaluation of risk factors for time to subsequent events after first stroke occurrence using a new weighted all-cause effect measure

2019 ◽  
Author(s):  
Ann-Kathrin Ozga ◽  
Bernhard Rauch ◽  
Frederick Palm ◽  
Christian Urbanek ◽  
Armin Grau ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Atrial Fibrillation ◽  
Recurrent Stroke ◽  
Composite Endpoint ◽  
Hazard Ratio ◽  
Specific Effects ◽  
Index Stroke ◽  
One Year ◽  
The One

Abstract Background : Risk factors for stroke include atrial fibrillation, hypertension, diabetes mellitus, smoking, and high cholesterol. However, the role of these factors on subsequent cardiovascular events or death is less clear due to therapeutic measures. We therefore aim to get insights into the persistence of known risk factors on subsequent stroke or death one year after the first stroke and to illustrate how the new weighted all-cause hazard ratio can ease the interpretation of competing time-to-event endpoints with different clinical relevance. Methods : This study evaluates the one year follow-up of 470 first ever stroke cases identified in the area of Ludwigshafen, Germany, with 23 deaths and 34 subsequent stroke events. The recently introduced weighted all-cause hazard ratio was used which allows a weighting of the competing endpoints in a composite endpoint. We extended this approach to allow adjustment for covariates. The investigated risk factors were atrial fibrillation, hypertension, diabetes mellitus, smoking, and hypercholesterolemia adjusting for age and sex. Results : None of these meanwhile treated risk factors of which some have been modified after first stroke remained to be associated with subsequent death or stroke. Cause-specific effects point sometimes into opposite directions. Conclusions : Using the new weighted hazard ratio, we can support that well established risk factors for the occurrence of an index stroke are no good predictors of further disease progress defined by death or recurrent stroke. It has been demonstrated that the new weighted hazard ratio provides interpretation advantages over the common all-cause hazard ratio.

A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 4043-4043
Author(s):  
Hiroo Katsuya ◽  
Koichi Suyama ◽  
Kazuma Kobayashi ◽  
Naoki Izawa ◽  
Yoshikazu Uenosono ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Survival Rate ◽  
Elderly Patients ◽  
Line Treatment ◽  
Efficacy And Safety ◽  
First Line ◽  
Recurrent Gastric Cancer ◽  
One Year ◽  
The One ◽  
First Line Treatment

4043 Background: Elderly patients are often intolerable in the combination with cytotoxic agents. Therapy with S-1 alone is a key option for initial chemotherapy for Japanese elderly patients with unresectable gastric cancer in clinical practice. However, there are some cases in which the antitumor effects with S-1 alone are insufficient. We aimed to investigate the efficacy and safety of S-1 plus ramucirumab therapy to elderly patients with advanced/recurrent gastric cancer. Methods: Patients aged 70 years and older with previously untreated unresectable or recurrent gastric cancer patients were included in Japan. They received S-1 therapy (40-60 mg twice daily for 28 days, every 6 weeks) plus ramucirumab therapy (8 mg/kg, every 2 weeks) until disease progression. The primary endpoint was the one-year survival rate and null hypothesis of one-year survival was set as 40%, which is the lower bound of the 95% confidence interval in previously reported studies on S-1 therapy. The secondary endpoints included progression-free survival (PFS), overall survival (OS), response rate (RR), and safety. Results: Between September 2017 and November 2019, 48 patients were enrolled in this study. The characteristics of patients were male/female: 34/14, median age: 77.5 years (range: 71-87), and PS (0/1): 20/28. The one-year survival rate was 65.2% (95% confidence interval 49.8-78.6%), which means this trial met the primary endpoint. The median OS and PFS were 16.4 months (95%CI:12.0–20.7) and 5.8 months (95%CI:4.0–7.2), respectively. The best RR (CR+PR) was 60.9%. The frequent grade 3 or grade 4 adverse events were neutropenia (27.7%), anorexia (23.4%), anemia (19.1%), hypertension (14.9%), leucopenia (12.8%) and hypoalbuminemia (12.8%). Conclusions: Based on the observed efficacy and safety, S-1 plus ramucirumab is an appropriate first-line treatment for elderly patients with advanced/recurrent gastric cancer. Clinical trial information: UMIN000028309.

scholarly journals Outcome of Rhabdomyosarcoma in First Year of Life: Children’s Cancer Hospital 57357 Egypt

Sarcoma ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Enas El Nadi ◽  
Emad A. H. Moussa ◽  
Wael Zekri ◽  
Hala Taha ◽  
Alaa Yones ◽  
...  
Keyword(s):  
Overall Survival ◽  
Survival Rate ◽  
Multimodality Treatment ◽  
Treatment Modalities ◽  
First Year ◽  
Female Ratio ◽  
Free Survival ◽  
Cancer Hospital ◽  
One Year ◽  
First Year Of Life

Background. Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children. Fifty percent of RMS cases occur in the first 10 years of life and less commonly in infants younger than one-year old. These infants require adapted multimodality treatment approaches.Patients and Methods. We analyzed patients’ characteristics, treatment modalities, and the outcome for RMS infants treated at Children’s Cancer Hospital Egypt (CCHE) between July 2007 and December 2010 and compared them to patients above one year treated on the same protocol.Results. Out of the 126 RMS treated during this period, 18 were below the age of one year. The male: female ratio was 1.25 : 1. The median age at diagnosis was 0.7 ± 0.2 years. Most of the cases (27.8%) were presented in head and neck regions. The estimated 4-years failure-free survival and overall survival for infants were 49 ± 12% and 70 ± 12%, respectively. These failure-free survival rate and overall survival rate did not differ from those for older patients (P=0.2).Conclusion. Infants with RMS are a unique group of RMS who needs special concerns in tailoring treatment in addition to concerns regarding toxicity and morbidity in infants.Corrigendum to “Outcome of Rhabdomyosarcoma in First Year of Life: Children’s Cancer Hospital 57357 Egypt”

scholarly journals Y-shaped Ventriculo-peritoneal Shunt for Adult Complicated Hydrocephalus: Report of 28 Illustrative Cases

2020 ◽  
Author(s):  
Xiaohui Ren ◽  
Chuanwei Yang ◽  
Xiangrong Li ◽  
Yonggang Wang ◽  
Song Lin
Keyword(s):  
Survival Rate ◽  
Cox Regression ◽  
Tumor Resection ◽  
Long Term Outcome ◽  
Frontal Horn ◽  
First Choice ◽  
Multiloculated Hydrocephalus ◽  
One Year ◽  
The One ◽  
Ventriculo Peritoneal Shunt

Abstract ObjectiveTo investigate the effectiveness of Y-shaped ventriculo-peritoneal shunt (VPS) (one abdominal tip connected with double or triple ventricular tips by one or two Y-shaped connectors) in the treatment of adult complicated hydrocephalus, we analyzed the long-term outcome and reported some illustrative cases.MethodsAmong 1,100 VPS surgeries between 2012 and 2017 in neurosurgery of Beijing Tiantan Hospital, twenty-eight (2.5%) adult patients with multiloculated hydrocephalus treated with Y-shaped shunt were analyzed.ResultsNineteen patients underwent Y-shaped VPS (bilateral frontal horn shunt) before or without tumor resection/stereotactic biopsy, 7 patients underwent Y-shaped VPS after tumor resection (5 bilateral and 2 triple shunts), and the other 2 patients underwent sequential bilateral VPS (unilateral VPS with additional contralateral ventricular tip by Y-shaped connector 6 months later). The one-year and two-year hydrocephalus-free survival rate for was both 88.7%. The one-year and two-year overall survival rate was both 66.7%. Cox regression confirmed that the OS is correlated with tumor grades. ConclusionsY-shaped VPS strategy is an easy and reliable option for multiloculated hydrocephalus, which can be used as the first choice for some indications.

Sign in / Sign up

Export Citation Format

Share Document